| Literature DB >> 22792516 |
Nahla N Salama1, Mohammed A El Ries, Safaa Toubar, Maha Abd El Hamid, Mohammed I Walash.
Abstract
The thermal behavior of some sulfone-containing drugs, namely, dapsone (DDS), dimethylsulfone (MSM), and topiramate (TOP) in drug substances, and products were investigated using different thermal techniques. These include thermogravimetry (TGA), derivative thermogravimetry (DTG), differential thermal analysis (DTA), and differential scanning calorimetry (DSC). The thermogravimetric data allowed the determination of the kinetic parameters: activation energy (E(a)), frequency factor (A), and reaction order (n). The thermal degradation of dapsone and topiramate was followed a first-order kinetic behavior. The calculated data evidenced a zero-order kinetic for dimethylsulfone. The relative thermal stabilities of the studied drugs have been evaluated and follow the order DDS > TOP > MSM. The purity was determined using DSC for the studied compounds, in drug substances and products. The results were in agreement with the recommended pharmacopoeia and manufacturer methods. DSC curves obtained from the tablets suggest compatibility between the drugs, excipients and/or coformulated drugs. The fragmentation pathway of dapsone with mass spectrometry was taken as example, to correlate the thermal decomposition with the resulted MS-EI. The decomposition modes were investigated, and the possible fragmentation pathways were suggested by mass spectrometry.Entities:
Year: 2012 PMID: 22792516 PMCID: PMC3389717 DOI: 10.1155/2012/439082
Source DB: PubMed Journal: J Anal Methods Chem ISSN: 2090-8873 Impact factor: 2.193
Figure 1Thermal decomposition TGA/DTG and DTA for Dapsone, dimethyl sulfone, and Topiramate.
Thermal decomposition data of TGA, DTG, and DTA curves of Dapsone, dimethyl sulfone, and Topiramate.
| Drugs | TGA and DTG | DTA | ||||||
|---|---|---|---|---|---|---|---|---|
| 1st reaction temperature | 2nd reaction temperature | Endothermic peaks (°C) | Exothermic peaks (°C) | |||||
| Onset | End set | %wt loss | Onset | End set | %wt loss | |||
| Dapsone | 339 | 393.41 | 52.174 | 393.41 | 726 | 47.91 | 185.12 (refer to mp), 368.83, 639.34 | 686.34 |
| Dimethyl sulfone | 170 | 299.13 | 94.53 | 299.13 | 355 | 5.71 | 108.81 (refer to mp), 215.9 | 852.23 |
| Topiramate | 151 | 393.46 | 73.19 | 393.4 | 722.43 | 25.26 | 130.53 (refer to mp), 154.07 | 181.07, 350.80 |
Kinetic parameters from the Arrhenius equation for Dapsone, Topiramate, and dimethyl sulfone.
| Drug | Temperature range (°C) | Order of reaction |
| ln |
|
|---|---|---|---|---|---|
| Dapsone | 339–393 | 1 | 485.87 | 88.255 | 0.9921 |
| Topiramate | 151–393 | 1 | 93.78 | 13.993 | 0.9957 |
| Dimethyl sulfone | 170–299 | zero | 51.006 | 11.815 | 0.9903 |
Scheme 1The suggested thermal degradation of Dapsone.
Kinetic parameters obtained by the methods of Horowitz and Metzger (HM) and Coats and Redfern (CR) for Dapsone and Topiramate.
| Drugs | Temperature range (°C) |
|
|
| ||
|---|---|---|---|---|---|---|
| HM | CR | HM | CR | CR | ||
| Dapsone | 339–393 | 485 | 454 | 1 | 1 | 1.27 × 1032 |
| Topiramate | 151–393 | 136.8 | 144.43 | 1 | 1 | 7.6 × 108 |
Scheme 2Mass spectral fragmentation pathways of Dapsone.
Degree of purity and melting point of Dapsone, dimethyl sulfone, and Topiramate in drug substances by DSC, melting point apparatus, and pharmacopoeial and reported methods.
| Drugs | Degree of purity% | Melting point (°C) | |||
|---|---|---|---|---|---|
| DSC* | Pharmacopoeial/reported | DSC | Mp apparatus | Pharmacopoeial/reported | |
| Dapsone | 99.66 | 100.29** | 175.62 | 177 | 175–181 |
| Dimethyl sulfone | 99.73 | 99.36*** | 106.99 | 109 | 108–110 |
| Topiramate | 98.27 | 98.00**** | 122.41 | 125 | 122–126 |
*Mean of five instrumental run.
**Official BP 2010.
***Manufacturer GC method supplied by Eva Pharma, Egypt.
****Official USP 2011.
Figure 2DSC profile of Dapsone drug substance (a), and Dapsone tablet (b).
Figure 3DSC profile of dimethyl sulfone drug substance (a), MSM tablet (b), and Genuphil tablet (c).
Figure 4DSC profile of Topiramate drug substance (a), Topamax tablet (b).
Application of the proposed DSC method for determination of the claimed amount of Dapsone, dimethyl sulfone, and Topiramate in their pharmaceutical formulations.
| Dosage forms | Claimed amount* % by the proposed DSC | Claimed amount % by pharmacopoeial and/or reported methods |
|---|---|---|
| Dapsone (50 mg of Dapsone/tab) | 91.25 | 96.28** |
| MSM (100 mg MSM/tab) | 95.36 | 94.56*** |
| Genuphil tablet (375 mg MSM/tab) | 96.33 | — |
| Topamax (25 mg TOP/tab) | 93.54 | 94.26**** |
*Mean of five instrumental run.
**Official BP 2010.
***Manufacturer GC method supplied by Eva Pharma, Egypt.
****Official USP 2012.